Adjuvant Therapy for Colon Cancer

被引：20

作者：

Saltz, Leonard B. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Colorectal Oncol Sect, Dept Med, New York, NY 10065 USA

[2] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10065 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2010年 / 19卷 / 04期

关键词：

Adjuvant therapy; Colorectal cancer; Disease-free survival; 5-FluorouracilU; FLUOROURACIL PLUS LEUCOVORIN; METASTATIC COLORECTAL-CANCER; STAGE-II; PHASE-III; INTRAVENOUS FLUOROURACIL; MISMATCH-REPAIR; CHEMOTHERAPY; OXALIPLATIN; LEVAMISOLE; RISK;

D O I：

10.1016/j.soc.2010.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients are not at risk of dying from a tumor that has been removed, they are at risk of dying from residual microscopic disease not removed at the time of operation Thus, the goal of an adjuvant treatment, be it chemotherapy, radiation therapy, immunotherapy, or dietary and lifestyle manipulations, is to eradicate any residual, albeit microscopic, metastatic disease that might remain Stage I disease carries an excellent prognosis and at present there are no compelling data to support adjuvant chemotherapy for patients with this early stage Stage II colon cancer also has a good prognosis after operation alone and represents the most complicated and contentious area in decisions regarding the use of adjuvant chemotherapy Stage III colorectal cancer (TanyN(1-2)M(0)) represents a group at a higher risk of recurrence, and this population is routinely given adjuvant chemotherapy in the absence of a medical or psychiatric contraindication

引用

页码：819 / +

页数：11

共 26 条

[1]

Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO

[2]

2-L

[3] Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147 [J].